Aethlon Medical Inc
NASDAQ:AEMD
Net Margin
Aethlon Medical Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Aethlon Medical Inc
NASDAQ:AEMD
|
2.9m USD | N/A | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
230.4B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
172.2B USD |
29%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
157B USD |
14%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
149.8B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
119.5B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
53.8B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
57.1B USD |
8%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51.3B USD |
24%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.7B USD |
73%
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
42.3B USD |
27%
|
Aethlon Medical Inc
Glance View
Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. The company is headquartered in San Diego, California and currently employs 10 full-time employees. The firm operates through two segments: Aethlon and ESI. The Aethlon segment represents its therapeutic business activities. The ESI segment represents its diagnostic business activities. The firm's product, Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The Aethlon Hemopurifie is designed for the single-use removal of exosomes and life-threatening viruses from the human circulatory system. In cancer, the Aethlon Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis. The Company, through its subsidiary Exosome Sciences, Inc. (ESI) is developing exosome-based biomarkers in patients with, or at risk for, a number of cancers.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Aethlon Medical Inc's most recent financial statements, the company has Net Margin of 0%.
You don't have any saved screeners yet